Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas

Junning Cao, Zhiming Li, MD PhD, Jianfeng Zhou, MD PhD, Dongmei Ji, MD PhD, Weina Shen, PhD, Peng Sun, MD, Yu Wang, MD, Dengju Li, MD, Zhenya Hong, MDPhD, Gaoxiang Wang, MDPhD, Xianlin Duan, MD, Chen Yu, MD, Yu Cai, PhD, Weiguo Su, PhD

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-136013

Published: 2020

Journal Articles

Proteomic Profiling Identifies c-KIT and 53BP1 As Resistance Factors of AML Relapse Post Allogeneic Stem Cell Transplantation with G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning

Zhihong Zeng, MD, Hongbo Lu, MD, Rui-Yu Wang, MD, Wenbin Lu, PhD, Julianne Chen, Christopher B Benton, MD, Keith Baggerly, PhD, Elizabeth J Shpall, MD, Richard E Champlin, MD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2528.

https://doi.org/10.1182/blood.V130.Suppl_1.2528.2528

Published: 2017

Journal Articles

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

Blood (2016) 128 (22): 2745.

https://doi.org/10.1182/blood.V128.22.2745.2745

Published: 2016

Journal Articles

Role of Mesenchymal Stem Cell Galectin 3 in the AML Tumor Microenvironment

Peter Ruvolo, PhD, Yihua Qiu, MD, Vivian Ruvolo, MS, Rui-Yu Wang, MD PhD, Zhihong Zeng, MD, Jared Burks, PhD, Rongqing Pan, MS, Numsen Hail, Jr., PhD, Teresa McQueen, Suk-Young Yoo, Steven M. Kornblau, MD, Michael Andreeff, MD PhD

Blood (2015) 126 (23): 1198.

https://doi.org/10.1182/blood.V126.23.1198.1198

Published: 2015

Journal Articles

Acute Myelogenous Leukemia (AML) Mesenchymal Stromal Cell (MSC) Have Distinct Protein Expression Patterns Compared to Normal MSC

Steven M. Kornblau, MD, Peter Ruvolo, PhD, Rui-Yu Wang, MD PhD, Vivian Ruvolo, MS, Yihua Qiu, MD, Venkata Lokesh Battula, PhD, Zhihong Zeng, MD, Teresa McQueen, Suk-Young Yoo, Marina Konopleva, MD PhD, Michael Andreeff, MD, PhD

Blood (2015) 126 (23): 3813.

https://doi.org/10.1182/blood.V126.23.3813.3813

Published: 2015

Journal Articles

Reverse Phase Protein Analysis of Mesenchymal Stem Cells from AML Patients and Healthy Donors Reveals Distinct Patterns of Protein Expression Reflecting Differences in Senescence, Differentiation and Survival Signaling

Peter P. Ruvolo, PhD, Venkata Lokesh Battula, PhD, YiHua Qui, MD, Vivian R Ruvolo, MA, Rodrigo Jacamo, PhD, Zhihong Zeng, MD, Rui-Yu Wang, MD PhD, Teresa McQueen, BS, Arvind Rao, SukYoung Yoo, Phuong M Le, Numsen Hail, PhD, Bing Z Carter, PhD, Steven M. Kornblau, MD, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 4376.

https://doi.org/10.1182/blood.V124.21.4376.4376

Published: 2014

Journal Articles

Acute Myeloid Leukemia Cells Acquire Chemo-Resistance By Inducing Osteoblast Differentiation in Mesenchymal Stem Cells through up-Regulation of RUNX2

Venkata Lokesh Battula, PhD, Phuong M Le, Jeffrey Sun, BS, Teresa McQueen, BS, Anitha Somanchi, MS, Rui-Yu Wang, MD PhD, Dirk Strunk, MD, Elizabeth J Shpall, MD, Peter P. Ruvolo, PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 2929.

https://doi.org/10.1182/blood.V124.21.2929.2929

Published: 2014

Journal Articles

MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML

Zhihong Zeng, MD, Rui-Yu Wang, MD PhD, Yuexi Shi, MD, Yihua Qiu, MD, Duncan H Mak, MS, Kevin Coombes, PhD, Suk Young Yoo, PhD, Katti Jessen, Yi Liu, PhD, Christian Rommel, PhD, Hagop M. Kantarjian, MD, Steven M. Kornblau, MD, David Fruman, PhD, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 3613.

https://doi.org/10.1182/blood.V124.21.3613.3613

Published: 2014

Journal Articles

Phosphorylation Of GSK3β Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells

Peter P. Ruvolo, PhD, Rui-yu Wang, MD, PhD, Vivian R Ruvolo, MA, Rodrigo Jacamo, PhD, Teresa McQueen, BS, Gautam Borthakur, MD, Yihua Qiu, MD, Kevin R. Coombes, PhD, Nianxiang Zhang, Elizabeth J Shpall, MD, Richard E Champlin, MD, Ramiro Garzon, MD, Guido Marcucci, MD, Carlo M. Croce, MD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Steven M. Kornblau, MD

Blood (2013) 122 (21): 2551.

https://doi.org/10.1182/blood.V122.21.2551.2551

Published: 2013

Journal Articles

Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo

Blood (2013) 122 (21): 3685.

https://doi.org/10.1182/blood.V122.21.3685.3685

Published: 2013

Journal Articles

Mesenchymal Stem Cells Vs. Mesenchymal Stem Cells Combined With Cord Blood For Treating Engraftment Failure Following Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective Study

YiYing Xiong, Fan Qian, Fen Huang, Yu Zhang, Yu Wang, MD, Xiaoyong Chen, Zhiping Fan, Hongsheng Zhou, Yang Xiao, MD, Xiaojun Xu, Min Dai, PhD, Na Xu, Jing Sun, MD, Peng Xiang, Xiaojun Huang, Qifa Liu, MD

Blood (2013) 122 (21): 3693.

https://doi.org/10.1182/blood.V122.21.3693.3693

Published: 2013

Journal Articles

Low WT1 Expression At Diagnosis Is a Strong Predictor On Poor Outcome In Patients With t(8;21) Acute Myeloid Leukemia

Ya-Zhen Qin, MS, Hong-Hu Zhu, MD, Qian Jiang, Dai-Hong Liu, MD, PhD, Hao Jiang, Lan-Ping Xu, MD, Huan Chen, Yu Wang, MD, Xiao-hui Zhang, MD, PhD, Jun-Yue Chai MM, Li-Ru Wang, MD, Yan-Rong Liu, MS, Xiao-Jun Huang, MD, PhD

Blood (2013) 122 (21): 1346.

https://doi.org/10.1182/blood.V122.21.1346.1346

Published: 2013

Journal Articles

A Clinical Study On Rituximab for Probable and Proven EBV Disease Post Haematopoietic Stem-Cell Transplantation

Lanping Xu, Daihong Liu, Kaiyan Liu, MD, Chunli Zhang, Fengrong Wang, Jingzhi Wang, Yu Wang, MD, Huan Chen, Yuanyuan Zhang, Chenhua Yan, Wei Han, MD, Yuhong Chen, MD, PhD, Ting Zhao, Xiao-Hui Zhang, Xiaojun Huang

Blood (2012) 120 (21): 4512.

https://doi.org/10.1182/blood.V120.21.4512.4512

Published: 2012

Journal Articles

All-Trance Retinoid Acid (ATRA) Makes Refractory Immune Thrombocytopenia (RITP) Less Refractory: A Retrospective Study of Ritp Patients Treated with Combination Therapies Including ATRA

Min Wang, MD, Xiao-hui Zhang, MD, PhD, Wei Han, MD, Yu Wang, MD, Dai-Hong Liu, MD, PhD, Lan-Ping Xu, MD, Kai-Yan Liu, MD, Hai-xia Fu, MD, Meng Lv, MD, Yi Zhou, MD, Xiao-Jun Huang, MD

Blood (2012) 120 (21): 3338.

https://doi.org/10.1182/blood.V120.21.3338.3338

Published: 2012

Journal Articles

Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients

Michael Andreeff, MD, PhD, Zhihong Zeng, PhD, Mary A Kelly, RN, Rui-yu Wang, MD, PhD, Teresa McQueen, BS, Seshagiri Duvvuri, Gul Nowshad, Gautam Borthakur, MD, Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Elias Jabbour, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD, PhD

Blood (2012) 120 (21): 142.

https://doi.org/10.1182/blood.V120.21.142.142

Published: 2012

Journal Articles

Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse

Blood (2012) 120 (21): 360.

https://doi.org/10.1182/blood.V120.21.360.360

Published: 2012

Journal Articles

Prolonged Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Its Association with an Increase in CD8+ CX3CR1+ Cells in Bone Marrow.

Xiao-hui Zhang, MD, PhD, Guo-xiang Wang, MD, Yan-rong Liu, MD, Lan-Ping Xu, MD, Kai-Yan Liu, MD, Wei Han, MD, Yu Wang, MD, Hai-xia Fu, MD, Meng Lv, MD, Min Wang, MD, Yi Zhou, MD, Xiao-Jun Huang, MD

Blood (2012) 120 (21): 3077.

https://doi.org/10.1182/blood.V120.21.3077.3077

Published: 2012

Journal Articles

Combined Use of WT1 and Flow Cytometry Monitoring Can Promote Sensitivity of Predicting Relapse After Allogeneic HSCT without Affecting Specificity.

Xiaosu Zhao, Chenhua Yan, Daihong Liu, Lanping Xu, Yanrong Liu, Kaiyan Liu, MD, Yazhen Qin, Yu Wang, MD, Xiaojun Huang

Blood (2012) 120 (21): 3065.

https://doi.org/10.1182/blood.V120.21.3065.3065

Published: 2012

Journal Articles

Proteomic Profiling of AML Bone Marrow-Derived Mesenchymal Stem Cells (MSC) Reveals Marked Differences From Normal MSC.

Rui-yu Wang, MD, PhD, Yi Hua Qiu, MD, Suk Young Yoo, PhD, Teresa McQueen, BS, Ye Chen, PhD, Zhihong Zeng, MD, Kevin R. Coombes, PhD, Wendy D. Schober, MLT (ASCP), Marina Konopleva, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD

Blood (2012) 120 (21): 2355.

https://doi.org/10.1182/blood.V120.21.2355.2355

Published: 2012

Journal Articles

p53 Activation of Mesenchymal Stromal Cells (MSC) Partially Abrogates Microenvironment-Mediated Resistance to FLT3 Inhibition In FLT3/ITD AML

Kensuke Kojima, MD, PhD, Teresa McQueen, Elizabeth J. Shpall, MD, Rui-Yu Wang, MD, PhD, Michael Andreeff, MD, PhD

Blood (2010) 116 (21): 2151.

https://doi.org/10.1182/blood.V116.21.2151.2151

Published: 2010

NARROW

Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas

Proteomic Profiling Identifies c-KIT and 53BP1 As Resistance Factors of AML Relapse Post Allogeneic Stem Cell Transplantation with G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning

The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia

Role of Mesenchymal Stem Cell Galectin 3 in the AML Tumor Microenvironment

Acute Myelogenous Leukemia (AML) Mesenchymal Stromal Cell (MSC) Have Distinct Protein Expression Patterns Compared to Normal MSC

Reverse Phase Protein Analysis of Mesenchymal Stem Cells from AML Patients and Healthy Donors Reveals Distinct Patterns of Protein Expression Reflecting Differences in Senescence, Differentiation and Survival Signaling

Acute Myeloid Leukemia Cells Acquire Chemo-Resistance By Inducing Osteoblast Differentiation in Mesenchymal Stem Cells through up-Regulation of RUNX2

MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML

Phosphorylation Of GSK3β Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells

Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo

Mesenchymal Stem Cells Vs. Mesenchymal Stem Cells Combined With Cord Blood For Treating Engraftment Failure Following Autologous Hematopoietic Stem Cell Transplantation: A Pilot Prospective Study

Low WT1 Expression At Diagnosis Is a Strong Predictor On Poor Outcome In Patients With t(8;21) Acute Myeloid Leukemia

A Clinical Study On Rituximab for Probable and Proven EBV Disease Post Haematopoietic Stem-Cell Transplantation

All-Trance Retinoid Acid (ATRA) Makes Refractory Immune Thrombocytopenia (RITP) Less Refractory: A Retrospective Study of Ritp Patients Treated with Combination Therapies Including ATRA

Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients

Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse

Prolonged Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Its Association with an Increase in CD8+ CX3CR1+ Cells in Bone Marrow.

Combined Use of WT1 and Flow Cytometry Monitoring Can Promote Sensitivity of Predicting Relapse After Allogeneic HSCT without Affecting Specificity.

Proteomic Profiling of AML Bone Marrow-Derived Mesenchymal Stem Cells (MSC) Reveals Marked Differences From Normal MSC.

p53 Activation of Mesenchymal Stromal Cells (MSC) Partially Abrogates Microenvironment-Mediated Resistance to FLT3 Inhibition In FLT3/ITD AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only